The invention relates to a pharmaceutical composition intended for the treatment of a viral infection by an influenza type A virus in an individual, which composition comprises a compound having the property of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, said compound having the property of binding to the viral-RNA-binding domain on said nucleoprotein. The invention also relates to a pharmaceutical composition intended for the treatment of a viral infection by an orthomyxovirus in an individual, which composition comprises a compound having the property of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, said compound having the property of binding to the viral-RNA-binding domain on the nucleoprotein of said viruses. The invention also relates to a compound having the property of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, said compound having the property of binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and to a method for identifying a compound having the property of binding at the level of the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses.L'invention porte sur une composition pharmaceutique destinée au traitement d'une infection virale par un virus Influenza de type A chez un sujet, laquelle composition comprend un composé ayant la propriété d'agir en tant qu'inhibiteur de la fixation de l'ARN viral à la nucléoprotéine des virus Influenza de type A, ledit composé ayant la propriété de se lier au domaine de liaison de l'ARN viral sur ladite nucléoprotéine. L'invention porte également sur une composition pharmaceutique destinée au traitement d'une infection virale par un Orthomyxo virus chez un sujet, laquelle composition comprend un composé ayant la propriété d'agir en tant qu'inhibiteur de la fixation de l'ARN viral à la nuclé
